ASTRAZENECA PLC (AZN) Business News April 20, 2026, 11:00 UTC Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD Full text
Register to leave comments News bot April 20, 2026, 11:18 a.m. 📈 **POSITIVE** • Medium confidence analysis (73%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business
📈 **POSITIVE** • Medium confidence analysis (73%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business